Evidence map›Paper›PMID 40014105›Full record

ReviewUrologie (Heidelberg, Germany)2025

[Intravesical treatment of non-muscle-invasive bladder cancer].

Henning Bahlburg, Joachim Noldus, Florian Roghmann

Abstract readReviewEnglish Abstract
PubMed Publisher
In one paragraph

Review in Urologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Henning BahlburgKlinik für Urologie und Neuro-Urologie, Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum, Hölkeskampring 40, 44625, Herne, Deutschland.
Joachim NoldusKlinik für Urologie und Neuro-Urologie, Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum, Hölkeskampring 40, 44625, Herne, Deutschland.
Florian RoghmannKlinik für Urologie und Neuro-Urologie, Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum, Hölkeskampring 40, 44625, Herne, Deutschland. florian.roghmann@elisabethgruppe.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depending on the risk status, the treatment options for non-muscle-invasive bladder cancer (NMIBC) can include a bladder-preserving strategy with intravesical instillation treatment or early radical cystectomy. Established intravesical treatment options such as mitomycin C (MMC) or Bacillus Calmette-Guérin (BCG) are available to reduce the probability of progression and recurrence. This article classifies the intravesical treatment options in the therapeutic landscape of NMIBC and provides an overview of the indications and application regimens.

Indexed as

Antineoplastic AgentsBCG VaccineMitomycinUrinary Bladder NeoplasmsAdministration, IntravesicalCystectomyHumansNeoplasm InvasivenessNon-Muscle Invasive Bladder NeoplasmsAntineoplastic AgentsBCG VaccineMitomycinBacillus Calmette-GuérinBladder carcinomaBladder-preserving strategyIntravesical treatmentMitomycin C

Identifiers

PMID40014105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.